Literature DB >> 28343415

Is Therapeutic Hypothermia for Acute Respiratory Distress Syndrome the Future?

Adam J Hayek1, Heath D White1, Shekhar Ghamande1, Christopher Spradley1, Alejandro C Arroliga1.   

Abstract

INTRODUCTION: Severe acute respiratory distress syndrome (ARDS) has a high mortality, and there is limited knowledge about management of severe ARDS refractory to standard therapy. Early evidence suggests that therapeutic hypothermia (TH) could be a viable treatment for acute respiratory failure. We present 2 cases where TH was successfully used to manage refractory ARDS on extracorporeal membrane oxygenation (ECMO) and a review of the literature around TH and acute respiratory failure.
RESULTS: We present 2 cases of ARDS secondary to H1N1 influenza and human metapneumovirus. Both patients were treated with the current evidence-based therapy for ARDS. Venovenous ECMO was used in both patients for refractory hypoxemia. Therapeutic hypothermia was applied for 24 hours with improved oxygenation. We did a review of the literature summarizing 38 patients in 10 publications where TH was successfully utilized in the treatment of acute respiratory failure.
CONCLUSION: Therapeutic hypothermia may be a viable salvage therapy for ARDS refractory to the current evidence-based therapy but needs further evaluation.

Entities:  

Keywords:  acute respiratory distress syndrome; extracorporeal membrane oxygenation; refractory hypoxemia; therapeutic hypothermia

Mesh:

Year:  2017        PMID: 28343415     DOI: 10.1177/0885066617701117

Source DB:  PubMed          Journal:  J Intensive Care Med        ISSN: 0885-0666            Impact factor:   3.510


  5 in total

Review 1.  Hypothesis: Fever control, a niche for alpha-2 agonists in the setting of septic shock and severe acute respiratory distress syndrome?

Authors:  F Petitjeans; S Leroy; C Pichot; A Geloen; M Ghignone; L Quintin
Journal:  Temperature (Austin)       Date:  2018-05-22

Review 2.  Adjunctive therapies during veno-venous extracorporeal membrane oxygenation.

Authors:  Federico Pappalardo; Andrea Montisci
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

3.  Hypermetabolism in critically ill patients with COVID-19 and the effects of hypothermia: A case series.

Authors:  Pey-Jen Yu; Hugh Cassiere; Karl Bocchieri; Sarah DeRosa; Shiraz Yar; Alan Hartman
Journal:  Metabol Open       Date:  2020-07-26

4.  The author replies.

Authors:  Jeffrey D Hasday
Journal:  Crit Care Med       Date:  2017-11       Impact factor: 7.598

5.  Cheap and simple, could it get even cooler? Mild hypothermia and COVID-19.

Authors:  Raul Dos Reis Ururahy; Marcelo Park
Journal:  J Crit Care       Date:  2021-01-30       Impact factor: 3.425

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.